Not specifiedRegulatory Approvalregulatorymid-term

TEVA Pharmaceuticals submits ANDA219413 for FDA review

Importance6/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

TEVA PHARMACEUTICALS, INC1 signalView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/18/2026, 12:32:06 AM

Assessment confidence: 61% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of ANDA219413 by TEVA Pharmaceuticals is significant as it represents a potential entry of a generic product into the market. This could alter pricing dynamics and competitive positioning within the relevant therapeutic area, which is currently unspecified. Regulatory context from FDA (FDA TA — ANDA219413) supports the near-term read. Assessment grounded in 19 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio and strategy teams should assess the potential market entry of this generic product and its implications for pricing and competition. The strongest clinical anchor is Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in Children (ClinicalTrials.gov), mechanism alignment (io ). In Not specified, 5 regulatory and 2 competitive items passed relevance filtering for TEVA PHARMACEUTICALS, INC.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This submission may impact the competitive landscape for generic alternatives in the relevant therapeutic area, depending on the product's specifics.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — ANDA219413 (FDA). Entity match (teva pharmaceuticals inc); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The standard review priority indicates a typical timeline for FDA evaluation, which could affect the timing of market entry for this generic product.

Key Risks

Elevated medium regulatory exposure for TEVA PHARMACEUTICALS, INC could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The introduction of a generic alternative could lead to price reductions and increased competition, impacting market share for existing branded products.
Upside for TEVA PHARMACEUTICALS, INC may improve if Lysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities. (PubMed) delivers favorable follow-through.
Portfolio and strategy teams should assess the potential market entry of this generic product and its implications for pricing and competition.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any subsequent approval announcements for ANDA219413.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — ANDA219413
FDAhigh relevance
Entity match (teva pharmaceuticals inc); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — ANDA220639
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VYEPTI (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in Children
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Pre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Relieving Postoperative Pain After Thoracoscopic Surgery
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Toxicity of Treatments for Non-tuberculous Mycobacterial Infections in Cancer Patients or Not
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
ACP-204 in Adults With Alzheimer's Disease Psychosis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Trial to Evaluate the Impact of Various Pragmatic Interventions to Increase Mammography Uptake Among Defaulted Repeat Screeners in Singapore
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Gut microbial markers of immunotherapy response in melanoma: a cross-cohort analysis including the first Russian dataset.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Nanomaterial-based vaccines: An advanced approach against rotavirus: A review article.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Nanotechnology-mediated podocyte injury repair: mechanistic exploration and therapeutic prospects.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

TEVA PHARMACEUTICALS, INC
ANDA219413

Commercial impact

medium

The introduction of a generic alternative could lead to price reductions and increased competition, impacting market share for existing branded products.

Regulatory impact

medium

The standard review priority indicates a typical timeline for FDA evaluation, which could affect the timing of market entry for this generic product.

What to watch

Monitor the FDA's review timeline and any subsequent approval announcements for ANDA219413.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.